Health

Ebola Outbreak: DRC Crosses 10,000 Cases as New Vaccines Join Trial

By Editorial Staff ·
Ebola Bundibugyo outbreak in DR Congo featured graphic

The Ebola outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC) has now passed 10,000 confirmed cases and more than 5,000 deaths, according to the World Health Organization. In its latest update, published on November 6, 2026, with data up to November 3, WHO said the virus is still spreading in many parts of eastern DRC, while Kenya and Nigeria are managing imported cases. Two new vaccine candidates, one of them developed with the Serum Institute of India, are being added to a clinical trial because no approved vaccine or treatment exists for this form of Ebola.

Latest Ebola Numbers From WHO

The WHO Disease Outbreak News report gives the following cumulative figures for the DRC:

Indicator (DRC, as of Nov 3) Figure
Confirmed cases 10,668
Deaths 5,198
Crude case fatality rate 48.7%
Recoveries 2,881
New confirmed cases since previous report 964
New confirmed deaths since previous report 511
Health zones affected 67, in eight provinces
Health zones with active transmission 51

Ituri province remains the worst hit, with 7,485 cases and 3,532 deaths. Nord-Kivu has reported 2,593 cases and 1,422 deaths, and has the highest provincial fatality rate at 54.8%.

A worrying detail in the report is where people are dying. Of 512 deaths recorded since October 21, 335 happened in the community rather than in treatment centres, and many of them were young children. Community deaths usually mean patients were not identified or isolated in time, which raises the risk of further spread through care at home and unsafe burials.

Contact tracing is also below target. WHO said an average of 86% of known contacts were followed up each day, short of the 95% goal.

Kenya, Nigeria and Other Countries

The outbreak was first confirmed in the DRC and Uganda in May 2026. Since then, a few cases have appeared outside the region:

  • Kenya: Nine confirmed cases and two deaths. Eight of these were linked to one imported case. No new case has been reported since October 19, and monitoring of the last contacts is due to end on November 11.
  • Nigeria: One imported case, confirmed on October 20 in Abuja. The patient was later evacuated to Switzerland for treatment. Health workers identified 62 contacts.
  • Uganda and France: Both have controlled their outbreaks since August, and Uganda has formally declared its outbreak over.
  • United Kingdom: One health and care worker who was infected has been medically evacuated and is being treated in London.

WHO said no new country has reported cases since its previous update.

Why Bundibugyo Ebola Is Hard to Stop

Ebola disease can be caused by different virus species. The licensed Ervebo vaccine is approved for Ebola virus, but WHO notes it is not approved for Bundibugyo virus. There is also no specific approved treatment for Bundibugyo virus disease.

Speaking at a media briefing on November 4, the WHO Director-General said transmission is slowing in some areas, but new hotspots keep appearing. He listed displacement of people, rainy weather, attacks on health care and difficult access to remote areas as factors making the response harder. WHO’s situation page also points to insecurity, a humanitarian crisis and heavy movement of people and goods in the affected region.

Vaccine Trial and the India Connection

A Phase 2/3 vaccine trial named Tumaini began on October 23 in Bunia in the DRC. It is led by the DRC’s National Institute for Biomedical Research with national and international partners, including WHO, and has started by testing Ervebo.

WHO expert groups have now recommended adding two vaccines designed specifically for Bundibugyo virus:

  • ChAdOx1 BDBV, developed by the University of Oxford with the Serum Institute of India
  • mRNA-1469, developed by Moderna

Both will join the trial once national approvals are in place. For India, the involvement of the Serum Institute is notable, as it shows the country’s vaccine makers playing a part in outbreak research far beyond South Asia. In Kenya, remaining patients are being given investigational treatments under approved protocols.

In his November 4 briefing remarks, the WHO chief stressed that vaccines do not replace basic measures such as early care, contact tracing, isolation, safe burials and working closely with communities.

Is There a Risk to Travellers?

WHO last reassessed the risk on August 14 and rated it very high in the DRC, high for countries sharing a land border with the DRC, and low for the rest of Africa and the world. The agency said it is now revising that assessment.

WHO advises against any restriction on travel to or trade with affected countries, and the Director-General urged nations that have imposed such restrictions to lift them, arguing they punish transparency and slow the response. He praised Kenya and Nigeria for reporting their cases quickly and openly.

For Indian travellers and others outside the region, WHO’s global risk rating remains low. Anyone who falls ill after visiting an affected area should seek medical care and share their travel history with the doctor.

Key highlights

  • DRC: 10,668 confirmed cases and 5,198 deaths as of November 3
  • Ituri and Nord-Kivu provinces are the worst affected
  • Kenya has 9 cases and 2 deaths; Nigeria has 1 imported case
  • No approved vaccine or treatment for Bundibugyo virus yet
  • Oxford and Serum Institute of India candidate to join the Tumaini trial

A Crowded Year for Health Emergencies in DRC

The Ebola response is running alongside other crises in the country. WHO said the DRC is also facing its worst cholera outbreak in decades, with more than 60,000 cases and 1,800 deaths this year. WHO plans a public webinar on the Ebola outbreak on November 12, and health officials will watch closely whether the new vaccines can help bring case numbers down. WHO has also been linking health to climate action ahead of the COP31 climate summit in Antalya.

This article is for general information only and is not medical advice. Please consult a doctor for health concerns.

More Health News